boostrix polio
glaxosmithkline as - difteritoksoid / clostridium tetani, toksoid / pertussistoksoid / filamentøst hemagglutinin / pertaktin / poliovirus type 1, inaktivert / poliovirus type 3, inaktivert / poliovirus type 2, inaktivert - injeksjonsvæske, suspensjon i ferdigfylt sprøyte - 2 ie/0.5 ml / 20 ie/0.5 ml / 8 mikrog/0.5 ml / 8 mikrog/0.5 ml / 2.5 mikrog/0.5 ml / 40 d-antigen enheter/0.5 ml / 32 d-antigen enheter/0.5 ml / 8 d-antigen enheter/0.5 ml
maasol -
ge healthcare as - albumin humant serum makroaggregater ad tc-99m makroalbumin - pulver til injeksjonsvæske, suspensjon
technescan lyomaa -
curium netherlands b.v. - albumin humant serum makroaggregater ad tc-99m makroalbumin - pulver til injeksjonsvæske, oppløsning
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - leddgikt, reumatoid - immunsuppressive - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - andre nervesystemet narkotika - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
xadago
zambon spa - safinamidmetansulfonat - parkinsonsykdom - anti-parkinson medisiner - xadago er indisert for behandling av voksne pasienter med idiopatisk parkinsons sykdom (pd) som add-on terapi til en stabil dose levodopa (l-dopa) alene eller i kombinasjon med andre pd legemidler i midt-sent varierende pasienter.
arcoxia 60 mg
orifarm as - etorikoksib - tablett, filmdrasjert - 60 mg
arcoxia 60 mg
orifarm as - etorikoksib - tablett, filmdrasjert - 60 mg
arcoxia 60 mg
orifarm as - etorikoksib - tablett, filmdrasjert - 60 mg
arcoxia 90 mg
farmagon - etorikoksib - tablett, filmdrasjert - 90 mg